The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. ⋯ In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Patients with relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to salvage chemotherapy. Gilteritinib is an oral, potent, selective FLT3 inhibitor with single-agent activity in relapsed or refractory FLT3-mutated AML. ⋯ Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).